Adjuvant chemotherapy: which patient? What regimen?

Area of Science:

• Oncology
• Genomics
• Breast Cancer Research

Background:

• Historically, early breast cancer (EBC) treatment decisions relied on clinicopathologic factors.
• Genomic analyses have advanced understanding of tumor biology and molecular subtypes.
• This allows for personalized treatment strategies in EBC.

Purpose of the Study:

• To highlight the role of genomic analyses in optimizing adjuvant chemotherapy decisions for EBC.
• To differentiate between identifying chemotherapy resistance and selecting optimal regimens.
• To emphasize the multifactorial approach needed for personalized EBC treatment.

Main Methods:

• Utilizing genomic analyses to determine molecular breast cancer subtypes.
• Correlating molecular subtypes with chemotherapy response and benefit.
• Integrating genomic data with clinicopathologic factors and patient characteristics.

Main Results:

• Genomic assays can identify EBC patients with chemotherapy-resistant tumors, particularly luminal A-like breast cancer, who may avoid chemotherapy.
• These assays do not specify the most appropriate chemotherapy regimen.
• Treatment decisions require a comprehensive approach.

Conclusions:

• Genomic profiling is crucial for de-escalating chemotherapy in select EBC patients.
• Optimal chemotherapy regimen selection necessitates integrating tumor biology, stage, and patient factors.
• Personalized medicine in EBC requires a holistic evaluation beyond molecular subtype alone.